Delivery strategies of amphotericin B for invasive fungal infections

被引：3

作者：

Xiaochun Wang ^{[1
]}

Imran Shair Mohammad ^{[2
]}

Lifang Fan ^{[3
]}

Zongmin Zhao ^{[4
]}

Md Nurunnabi ^{[5
]}

Marwa A.Sallam ^{[6
]}

Jun Wu ^{[7
]}

Zhongjian Chen ^{[8
]}

Lifang Yin ^{[1
]}

Wei He ^{[1
]}

机构：

[1] Department of Pharmaceutics,China Pharmaceutical University

[2] School of Pharmaceutical Sciences,Sun Yat-sen University,University Town

[3] Jiangsu Aosaikang Pharmaceutical Co.,Ltd.

[4] School of Engineering and Applied Sciences,Harvard University

[5] Department of Pharmaceutical Sciences,School of Pharmacy,University of Texas at El Paso

[6] Department of Industrial Pharmacy,Faculty of Pharmacy,Alexandria University

[7] Department of Geriatric Cardiology,Jiangsu Provincial Key Laboratory of Geriatrics,the First Affiliated Hospital of Nanjing Medical University

[8] Shanghai Skin Disease Hospital,Tongji University School of Medicine

来源：

ActaPharmaceuticaSinicaB | 2021年 / 11卷 / 08期

基金：

中国国家自然科学基金;

关键词：

D O I：

暂无

中图分类号：

R943 [制剂学];

学科分类号：

摘要：

Invasive fungal infections(IFIs) represent a growing public concern for clinicians to manage in many medical settings, with substantial associated morbidities and mortalities. Among many current therapeutic options for the treatment of IFIs, amphotericin B(AmB) is the most frequently used drug.AmB is considered as a first-line drug in the clinic that has strong antifungal activity and less resistance.In this review, we summarized the most promising research efforts on nanocarriers for AmB delivery and highlighted their efficacy and safety for treating IFIs. We have also discussed the mechanism of actions of AmB, rationale for treating IFIs, and recent advances in formulating AmB for clinical use. Finally, this review discusses some practical considerations and provides recommendations for future studies in applying AmB for combating IFIs.

引用

页码：2585 / 2604

页数：20

共 50 条

[1] Delivery strategies of amphotericin B for invasive fungal infections
Wang, Xiaochun
Mohammad, Imran Shair
Fan, Lifang
Zhao, Zongmin
Nurunnabi, Md
Sallam, Marwa A.
Wu, Jun
Chen, Zhongjian
Yin, Lifang
He, Wei
ACTA PHARMACEUTICA SINICA B, 2021, 11 (08) : 2585 - 2604
[2] The value of amphotericin B in the treatment of invasive fungal infections
Klepser, Michael
JOURNAL OF CRITICAL CARE, 2011, 26 (02) : 225.e1 - 225.e10
[3] Lipid formulations of amphotericin B in the management of invasive fungal infections
Fohrer, Cecile
Nivoix, Yasmine
Moulin, Jean-Charles
Marcais, Ambroise
Herbrecht, Raoul
THERAPIE, 2006, 61 (03): : 235 - 242
[4] Amphotericin B lipid complex for the treatment of invasive fungal infections
Linden, PK
EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (11) : 2099 - 2110
[5] Polymer-Mediated Delivery of Amphotericin B for Fungal Infections
Chen, Yongnan
Liu, Fang
Jin, Qiao
MACROMOLECULAR RAPID COMMUNICATIONS, 2025,
[6] Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B
Sole, Amparo
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 : S161 - S165
[7] Renal impairment and Amphotericin B formulations in patients with invasive fungal infections
Saliba, Faouzi
Dupont, Bertrand
MEDICAL MYCOLOGY, 2008, 46 (02) : 97 - 112
[8] Diagnosis and Treatment of Invasive Fungal Infections Focus on Liposomal Amphotericin B
João F. Lacerda
Carlos Meneses Oliveira
Clinical Drug Investigation, 2013, 33 : 5 - 14
[9] Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections
Nivoix, Y
Zamfir, A
Lutun, P
Kara, F
Remy, V
Lioure, B
Rigolot, JC
Entz-Werlé, N
Letscher-Bru, V
Waller, J
Levêque, D
Koffel, JC
Beretz, L
Herbrecht, R
JOURNAL OF INFECTION, 2006, 52 (01) : 67 - 74
[10] Diagnosis and Treatment of Invasive Fungal Infections Focus on Liposomal Amphotericin B
Lacerda, Joao F.
Oliveira, Carlos Meneses
CLINICAL DRUG INVESTIGATION, 2013, 33 : S5 - S14

← 1 2 3 4 5 →